Athira Pharma, Inc. (NASDAQ:ATHA) Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its holdings in Athira Pharma, Inc. (NASDAQ:ATHA) by 25.5% during the second quarter, HoldingsChannel.com reports. The fund owned 550,353 shares of the company’s stock after buying an additional 111,759 shares during the period. Dimensional Fund Advisors LP’s holdings in Athira Pharma were worth $1,458,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. increased its stake in Athira Pharma by 84.1% in the first quarter. Jacobs Levy Equity Management Inc. now owns 497,475 shares of the company’s stock valued at $1,363,000 after purchasing an additional 227,278 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Athira Pharma by 281.5% during the first quarter. Acadian Asset Management LLC now owns 549,938 shares of the company’s stock worth $1,505,000 after buying an additional 405,793 shares during the last quarter. Mirador Capital Partners LP acquired a new position in Athira Pharma in the 1st quarter valued at about $57,000. American Century Companies Inc. raised its stake in Athira Pharma by 9.4% during the 2nd quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock valued at $103,000 after acquiring an additional 3,333 shares during the last quarter. Finally, Rothschild Investment LLC purchased a new stake in Athira Pharma during the 2nd quarter valued at approximately $34,000. Hedge funds and other institutional investors own 57.12% of the company’s stock.

Athira Pharma Price Performance

ATHA opened at $0.42 on Friday. Athira Pharma, Inc. has a 12 month low of $0.41 and a 12 month high of $4.30. The stock has a market capitalization of $15.99 million, a P/E ratio of -0.14 and a beta of 2.83. The business has a 50 day simple moving average of $1.63 and a 200-day simple moving average of $2.25.

Athira Pharma (NASDAQ:ATHA) last released its earnings results on Thursday, August 1st. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.05. Research analysts anticipate that Athira Pharma, Inc. will post -2.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Mizuho lowered Athira Pharma from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $5.00 to $0.50 in a report on Thursday, September 19th. JMP Securities cut shares of Athira Pharma from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 4th. Rodman & Renshaw downgraded shares of Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th. Finally, BTIG Research downgraded shares of Athira Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, September 4th.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.